Abstract CT093: Preliminary evidence of antitumor activity of Ipatasertib (Ipat) and Atezolizumab (A) in glioblastoma (GBM) patients (pts) with PTEN loss in the Phase 1 Ice-CAP trial (NCT03673787)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct093
Abstract: Background PTEN loss of function is frequent in GBM correlating with poor prognosis, impaired antitumor responses and reduced efficacy of Immune Checkpoint Inhibitors (ICI). Ipat is a potent, selective, small-molecule inhibitor of Akt. Ipat efficiently… read more here.
Keywords: pten loss; antitumor; loss; trial ... See more keywords